| Polio vaccination: past, present and future AS Bandyopadhyay, J Garon, K Seib, WA Orenstein Future microbiology 10 (5), 791-808, 2015 | 323 | 2015 |
| Engineering the live-attenuated polio vaccine to prevent reversion to virulence M Te Yeh, E Bujaki, PT Dolan, M Smith, R Wahid, J Konz, AJ Weiner, ... Cell host & microbe 27 (5), 736-751. e8, 2020 | 154 | 2020 |
| Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection S Su, SS Chaves, A Perez, T D'Mello, PD Kirley, K Yousey-Hindes, ... Clinical Infectious Diseases 59 (2), 252-255, 2014 | 149 | 2014 |
| The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study P Van Damme, I De Coster, AS Bandyopadhyay, H Revets, K Withanage, ... The Lancet 394 (10193), 148-158, 2019 | 146 | 2019 |
| Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine GR Macklin, KM O’Reilly, NC Grassly, WJ Edmunds, O Mach, ... Science 368 (6489), 401-405, 2020 | 122 | 2020 |
| The burden of influenza hospitalizations in infants from 2003 to 2012, United States SS Chaves, A Perez, MM Farley, L Miller, W Schaffner, ML Lindegren, ... The Pediatric infectious disease journal 33 (9), 912-919, 2014 | 98 | 2014 |
| Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4 … M O'Ryan, AS Bandyopadhyay, R Villena, M Espinoza, J Novoa, ... The Lancet Infectious Diseases 15 (11), 1273-1282, 2015 | 95 | 2015 |
| Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants … EJ Asturias, AS Bandyopadhyay, S Self, L Rivera, X Saez-Llorens, ... The Lancet 388 (10040), 158-169, 2016 | 79 | 2016 |
| Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical … X Sáez-Llorens, AS Bandyopadhyay, C Gast, T De Leon, R DeAntonio, ... The Lancet 397 (10268), 27-38, 2021 | 71 | 2021 |
| Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine IM Blake, M Pons-Salort, NA Molodecky, OM Diop, P Chenoweth, ... New England Journal of Medicine 379 (9), 834-845, 2018 | 63 | 2018 |
| Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials I De Coster, I Leroux-Roels, AS Bandyopadhyay, C Gast, K Withanage, ... The Lancet 397 (10268), 39-50, 2021 | 59 | 2021 |
| Rapid and sensitive direct detection and identification of poliovirus from stool and environmental surveillance samples by use of nanopore sequencing AG Shaw, M Majumdar, C Troman, Á O’Toole, B Benny, D Abraham, ... Journal of clinical microbiology 58 (9), 10.1128/jcm. 00920-20, 2020 | 50 | 2020 |
| Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different … E Clarke, Y Saidu, JU Adetifa, I Adigweme, MB Hydara, AO Bashorun, ... The Lancet Global Health 4 (8), e534-e547, 2016 | 50 | 2016 |
| Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants PF Wright, RI Connor, WF Wieland-Alter, AG Hoen, AW Boesch, ... The Lancet infectious diseases 16 (12), 1377-1384, 2016 | 49 | 2016 |
| A review of the most commonly used methods for sample collection in environmental surveillance of poliovirus G Matrajt, B Naughton, AS Bandyopadhyay, JS Meschke Clinical Infectious Diseases 67 (suppl_1), S90-S97, 2018 | 47 | 2018 |
| Polio elimination in Nigeria: a review UN Nasir, AS Bandyopadhyay, F Montagnani, JE Akite, EB Mungu, ... Human vaccines & immunotherapeutics 12 (3), 658-663, 2016 | 44 | 2016 |
| Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial X Sáez-Llorens, R Clemens, G Leroux-Roels, J Jimeno, SAC Clemens, ... The Lancet Infectious Diseases 16 (3), 321-330, 2016 | 44 | 2016 |
| Enabling accelerated vaccine roll-out for public health emergencies of international concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience GR Macklin, C Peak, M Eisenhawer, F Kurji, O Mach, J Konz, C Gast, ... Vaccine 41, A122-A127, 2023 | 41 | 2023 |
| Immunization against poliomyelitis and the challenges to worldwide poliomyelitis eradication JF Modlin, AS Bandyopadhyay, R Sutter The Journal of infectious diseases 224 (Supplement_4), S398-S404, 2021 | 41 | 2021 |
| Updated characterization of outbreak response strategies for 2019–2029: impacts of using a novel type 2 oral poliovirus vaccine strain DA Kalkowska, MA Pallansch, A Wilkinson, AS Bandyopadhyay, ... Risk Analysis 41 (2), 329-348, 2021 | 41 | 2021 |
